Alector(US:ALEC)2025-05-08 20:10Financial Performance - Collaboration revenue for Q1 2025 was $3.7 million, a decrease of 77.8% compared to $15.9 million in Q1 2024[10] - Alector reported a net loss of $40.5 million, or $0.41 per share, compared to a net loss of $36.1 million, or $0.38 per share, for the same period in 2024[13] - Total general and administrative expenses for Q1 2025 were $14.7 million, slightly up from $14.4 million in Q1 2024[12] - Management anticipates collaboration revenue for 2025 to be between $5 million and $15 million[14] Research and Development - Total research and development expenses for Q1 2025 were $33.6 million, down 25.6% from $45.2 million in Q1 2024[11] - The pivotal INFRONT-3 Phase 3 trial of latozinemab is on track to report topline data in Q4 2025[3] - Enrollment in the PROGRESS-AD Phase 2 trial of AL101 was completed ahead of schedule in April 2025[7] - Alector continues to advance its preclinical and early research pipeline, including brain-penetrant therapies for neurodegenerative diseases[8] Financial Position - Cash, cash equivalents, and investments totaled $354.6 million as of March 31, 2025, sufficient to fund operations into the second half of 2027[13] - Total liabilities as of March 31, 2025, were $313.7 million, down from $341.5 million at the end of 2024[19]